{
    "clinical_study": {
        "@rank": "1323", 
        "arm_group": {
            "arm_group_label": "Omega-3 Fatty Acids", 
            "arm_group_type": "Experimental", 
            "description": "15ml omega-3 liquid form, twice a day for 12 weeks (Total daily dosage:840mg DHA and 192mg EPA)"
        }, 
        "brief_summary": {
            "textblock": "This is a 12-week open label trial to evaluate whether omega-3 fatty acids is effective in\n      reducing the severity of autism and its comorbidities."
        }, 
        "brief_title": "Omega-3 Fatty Acids in Autism Spectrum Disorders", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Autism Spectrum Disorders", 
        "condition_browse": {
            "mesh_term": [
                "Autistic Disorder", 
                "Child Development Disorders, Pervasive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Between ages 5 and 18 years old\n\n          -  Diagnosed to have Autism, Asperger Syndrome, or PDDNOS by the DSM-IV criteria; met\n             the Autism or Spectrum classification for Autism Diagnostic Interview - Revised\n             (ADI-R) and Autism Diagnostic Observation Schedule (ADOS)\n\n          -  Written parental consent for participation\n\n          -  Those not on current standard-of-care treatments for ASD\n\n        Exclusion Criteria:\n\n          -  Below 5 and above 18 years old\n\n          -  No formal diagnosis of Autism, Asperger Syndrome or PDD-NOS\n\n          -  Without written parental consent for participation\n\n          -  Those with brain pathology such as serious head injury, epilepsy, etc.\n\n          -  Those on current standard-of-care treatment for ASD\n\n          -  Those with psychotic symptoms, self-injurious behaviours and/or suicidal tendency,\n             and other history of clinically significant medical conditions screened by the\n             attending doctor to have increase the risk associated with study participation\n\n          -  Those on other types of medication or supplements or with change in dose"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "5 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01695200", 
            "org_study_id": "DSRB: 2011/00028"
        }, 
        "intervention": {
            "arm_group_label": "Omega-3 Fatty Acids", 
            "intervention_name": "Omega-3 fatty acids", 
            "intervention_type": "Dietary Supplement"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 30, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Singapore", 
                    "country": "Singapore", 
                    "zip": "168937"
                }, 
                "name": "Institute of Mental Health"
            }
        }, 
        "location_countries": {
            "country": "Singapore"
        }, 
        "number_of_arms": "1", 
        "official_title": "The Role of Omega-3 Fatty Acids in the Management of Singaporean Children With Autism Spectrum Disorders", 
        "other_outcome": [
            {
                "measure": "Assessment of plasma fatty acid composition, measurements of DHA and EPA (components of omega-3), and total phospholipid count", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Assessment of dietary intake and nutritional intake of the child", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }
        ], 
        "overall_official": {
            "affiliation": "National Healthcare Group, Singapore", 
            "last_name": "Min Sung, MBBS, MMed", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Singapore: Health Sciences Authority", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in parent rated Social Responsiveness Scale (SRS) scores during treatment", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01695200"
        }, 
        "responsible_party": {
            "investigator_affiliation": "National Healthcare Group, Singapore", 
            "investigator_full_name": "Dr. Sung Min", 
            "investigator_title": "Senior Consultant", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in parent rated Child Behavior Checklist (CBCL) scores during treatment", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Change from baseline in teacher rated Teacher Report (TRF) scores during treatment", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Change from baseline in teacher rated Social Responsiveness Scale (SRS) scores during treatment", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Change from baseline in clinician rated Clinical Global Impression (Severity and Improvements) scores during treatment", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Change from baseline in clinician rated Global Assessment of Functioning (GAF) scores during treatment", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Children's Yale-Brown Obsessive Compulsive Scale modified for Pervasive Developmental Disorders (CYBOCS-PDD)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "National Healthcare Group, Singapore", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Healthcare Group, Singapore", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}